UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 783

Sortiert nach

Pattern of distant metastases in colorectal cancer: a SEER based study

Oncotarget, 2015-11, Vol.6 (36), p.38658-38666

2015

Volltextzugriff (PDF)

How psychological ownership over nutritional products affects purchase intentions of high-pressure working groups

Frontiers in nutrition (Lausanne), 2024-08, Vol.11, p.1401035

2024

Volltextzugriff (PDF)

A Potent and Orally Active Antagonist (SM-406/AT-406) of Multiple Inhibitor of Apoptosis Proteins (IAPs) in Clinical Development for Cancer Treatment

Journal of medicinal chemistry, 2011-04, Vol.54 (8), p.2714-2726

2011

Volltextzugriff (PDF)

MDM2 inhibitor APG-115 synergizes with PD-1 blockade through enhancing antitumor immunity in the tumor microenvironment

Journal for immunotherapy of cancer, 2019-11, Vol.7 (1), p.327-16, Article 327

2019

Volltextzugriff (PDF)

The impact of transparent packaging: how transparent packaging for organic foods affects tourists' green purchasing behavior

Frontiers in nutrition (Lausanne), 2024, Vol.11, p.1328596-1328596

2024

Volltextzugriff (PDF)

Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition

Proceedings of the National Academy of Sciences - PNAS, 2008-03, Vol.105 (10), p.3933-3938

2008

Volltextzugriff (PDF)

Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial

Journal of hematology and oncology, 2022-08, Vol.15 (1), p.113-17, Article 113

2022

Volltextzugriff (PDF)

Bcl-2 and Noxa are potential prognostic indicators for patients with gastroenteropancreatic neuroendocrine neoplasms

Endocrine, 2022-10, Vol.78 (1), p.159-168

2022

Volltextzugriff (PDF)

Discovery of a novel ALK/ROS1/FAK inhibitor, APG-2449, in preclinical non-small cell lung cancer and ovarian cancer models

BMC cancer, 2022-07, Vol.22 (1), p.1-752, Article 752

2022

Volltextzugriff (PDF)

Potent and Orally Active Small-Molecule Inhibitors of the MDM2−p53 Interaction

Journal of medicinal chemistry, 2009-12, Vol.52 (24), p.7970-7973

2009

Volltextzugriff (PDF)

FLT3 inhibition by olverembatinib (HQP1351) downregulates MCL-1 and synergizes with BCL-2 inhibitor lisaftoclax (APG-2575) in preclinical models of FLT3-ITD mutant acute myeloid leukemia

Translational oncology, 2022-01, Vol.15 (1), p.101244-101244, Article 101244

2022

Volltextzugriff (PDF)

Synergistic effects of Smac mimetic APG-1387 with anti-PD-1 antibody are attributed to increased CD3 + NK1.1 + cell recruitment secondary to induction of cytokines from tumor cells

Cancer cell international, 2024-05, Vol.24 (1), p.181-181, Article 181

2024

Volltextzugriff (PDF)

Structure-Based Design of Potent Small-Molecule Inhibitors of Anti-Apoptotic Bcl-2 Proteins

Journal of medicinal chemistry, 2006-10, Vol.49 (21), p.6139-6142

2006

Volltextzugriff (PDF)

The SMAC Mimetic APG-1387 Sensitizes Immune-Mediated Cell Apoptosis in Hepatocellular Carcinoma

Frontiers in pharmacology, 2018-11, Vol.9, p.1298-1298

2018

Volltextzugriff (PDF)

Discovery of Embelin as a Cell-Permeable, Small-Molecular Weight Inhibitor of XIAP through Structure-Based Computational Screening of a Traditional Herbal Medicine Three-Dimensional Structure Database

Journal of medicinal chemistry, 2004-05, Vol.47 (10), p.2430-2440

2004

Volltextzugriff (PDF)

Targeting Bcl-2 and Bcl-XL with nonpeptidic small-molecule antagonists

Seminars in oncology, 2003-10, Vol.30 (5), p.133-142

2003

Volltextzugriff (PDF)

A Comprehensive Pan-Cancer Analysis of the Regulation and Prognostic Effect of Coat Complex Subunit Zeta 1

Genes, 2023-04, Vol.14 (4), p.889

2023

Volltextzugriff (PDF)

Correction: Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial

Journal of hematology and oncology, 2023-02, Vol.16 (1), p.13-13, Article 13

2023

Volltextzugriff (PDF)

MDM2 inhibitor APG-115 exerts potent antitumor activity and synergizes with standard-of-care agents in preclinical acute myeloid leukemia models

Cell death discovery, 2021-05, Vol.7 (1), p.90-90, Article 90

2021

Volltextzugriff (PDF)

An MDM2 antagonist (MI-319) restores p53 functions and increases the life span of orally treated follicular lymphoma bearing animals

Molecular cancer, 2009-12, Vol.8 (1), p.115-115

2009

Volltextzugriff (PDF)

Induction of apoptosis and antitumor effects of a small molecule inhibitor of Bcl-2 and Bcl-xl, gossypol acetate, in multiple myeloma in vitro and in vivo

Oncology reports, 2013-08, Vol.30 (2), p.731-738

2013

Volltextzugriff (PDF)

Correction: Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial

Journal of hematology and oncology, 2022-10, Vol.15 (1), p.159-159, Article 159

2022

Volltextzugriff (PDF)

HDM-2 inhibition suppresses expression of ribonucleotide reductase subunit M2, and synergistically enhances gemcitabine-induced cytotoxicity in mantle cell lymphoma

Blood, 2011-10, Vol.118 (15), p.4140-4149

2011

Volltextzugriff (PDF)

Preclinical development of HQP1351, a multikinase inhibitor targeting a broad spectrum of mutant KIT kinases, for the treatment of imatinib-resistant gastrointestinal stromal tumors

Cell & bioscience, 2019-10, Vol.9 (1), p.88-88, Article 88

2019

Volltextzugriff (PDF)

Application of electro-hydraulic proportional control in cathode rod pulling out system of lead electrolysis

Journal of engineering (Stevenage, England), 2019-01, Vol.2019 (13), p.340-344

2019

Volltextzugriff (PDF)

1 – 25 von 783

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(705)
Mit Volltextzugriff
(751)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(521)
Technology
(229)
Life Sciences & Biomedicine
(207)
Physical Sciences
(138)
Humans
(122)
Computer Science
(115)
Engineering
(92)
Computer Science, Artificial Intelligence
(90)
Animals
(86)
Computer Science, Theory & Methods
(80)
Physics
(62)
Chemistry
(56)
Oncology
(56)
Engineering, Electrical & Electronic
(55)
Mice
(55)
Apoptosis
(47)
Cell Line, Tumor
(47)
Biological And Medical Sciences
(46)
Materials Science
(41)
Female
(40)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

Pattern of distant metastases in colorectal cancer: a SEER based study

How psychological ownership over nutritional products affects purchase intentions of high-pressure working groups

A Potent and Orally Active Antagonist (SM-406/AT-406) of Multiple Inhibitor of Apoptosis Proteins (IAPs) in Clinical Development for Cancer Treatment

MDM2 inhibitor APG-115 synergizes with PD-1 blockade through enhancing antitumor immunity in the tumor microenvironment

The impact of transparent packaging: how transparent packaging for organic foods affects tourists' green purchasing behavior

Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition

Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial

Bcl-2 and Noxa are potential prognostic indicators for patients with gastroenteropancreatic neuroendocrine neoplasms

Discovery of a novel ALK/ROS1/FAK inhibitor, APG-2449, in preclinical non-small cell lung cancer and ovarian cancer models

Potent and Orally Active Small-Molecule Inhibitors of the MDM2−p53 Interaction

FLT3 inhibition by olverembatinib (HQP1351) downregulates MCL-1 and synergizes with BCL-2 inhibitor lisaftoclax (APG-2575) in preclinical models of FLT3-ITD mutant acute myeloid leukemia

Synergistic effects of Smac mimetic APG-1387 with anti-PD-1 antibody are attributed to increased CD3 + NK1.1 + cell recruitment secondary to induction of cytokines from tumor cells

Structure-Based Design of Potent Small-Molecule Inhibitors of Anti-Apoptotic Bcl-2 Proteins

The SMAC Mimetic APG-1387 Sensitizes Immune-Mediated Cell Apoptosis in Hepatocellular Carcinoma

Discovery of Embelin as a Cell-Permeable, Small-Molecular Weight Inhibitor of XIAP through Structure-Based Computational Screening of a Traditional Herbal Medicine Three-Dimensional Structure Database

Targeting Bcl-2 and Bcl-XL with nonpeptidic small-molecule antagonists

A Comprehensive Pan-Cancer Analysis of the Regulation and Prognostic Effect of Coat Complex Subunit Zeta 1

Correction: Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial

MDM2 inhibitor APG-115 exerts potent antitumor activity and synergizes with standard-of-care agents in preclinical acute myeloid leukemia models

An MDM2 antagonist (MI-319) restores p53 functions and increases the life span of orally treated follicular lymphoma bearing animals

Induction of apoptosis and antitumor effects of a small molecule inhibitor of Bcl-2 and Bcl-xl, gossypol acetate, in multiple myeloma in vitro and in vivo

Correction: Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial

HDM-2 inhibition suppresses expression of ribonucleotide reductase subunit M2, and synergistically enhances gemcitabine-induced cytotoxicity in mantle cell lymphoma

Preclinical development of HQP1351, a multikinase inhibitor targeting a broad spectrum of mutant KIT kinases, for the treatment of imatinib-resistant gastrointestinal stromal tumors

Application of electro-hydraulic proportional control in cathode rod pulling out system of lead electrolysis

Suchergebnisse filtern